NCT Number: NCT06190899
Phase: PHASE1|PHASE2
Trial Summary: This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Celcuity Inc
Acronym:
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives